JP2015506942A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506942A5
JP2015506942A5 JP2014553292A JP2014553292A JP2015506942A5 JP 2015506942 A5 JP2015506942 A5 JP 2015506942A5 JP 2014553292 A JP2014553292 A JP 2014553292A JP 2014553292 A JP2014553292 A JP 2014553292A JP 2015506942 A5 JP2015506942 A5 JP 2015506942A5
Authority
JP
Japan
Prior art keywords
protein
fragment
pharmaceutical composition
apolipoprotein
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506942A (ja
JP6310398B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2012/021802 external-priority patent/WO2012100010A1/en
Application filed filed Critical
Priority claimed from PCT/US2012/066314 external-priority patent/WO2013109342A1/en
Publication of JP2015506942A publication Critical patent/JP2015506942A/ja
Publication of JP2015506942A5 publication Critical patent/JP2015506942A5/ja
Application granted granted Critical
Publication of JP6310398B2 publication Critical patent/JP6310398B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553292A 2012-01-19 2012-11-21 非グリコシル化アポリポタンパク質a−ivを用いて糖尿病を処置する方法 Expired - Fee Related JP6310398B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide
USPCT/US2012/021802 2012-01-19
US201261675692P 2012-07-25 2012-07-25
US61/675,692 2012-07-25
PCT/US2012/066314 WO2013109342A1 (en) 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein a-iv

Publications (3)

Publication Number Publication Date
JP2015506942A JP2015506942A (ja) 2015-03-05
JP2015506942A5 true JP2015506942A5 (https=) 2016-01-21
JP6310398B2 JP6310398B2 (ja) 2018-04-11

Family

ID=48799573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553292A Expired - Fee Related JP6310398B2 (ja) 2012-01-19 2012-11-21 非グリコシル化アポリポタンパク質a−ivを用いて糖尿病を処置する方法

Country Status (13)

Country Link
US (1) US9951120B2 (https=)
EP (1) EP2804618B1 (https=)
JP (1) JP6310398B2 (https=)
KR (1) KR20140117565A (https=)
CN (1) CN104066436B (https=)
AU (1) AU2012366182B2 (https=)
BR (1) BR112014017141A2 (https=)
CA (1) CA2860782A1 (https=)
EA (1) EA028230B1 (https=)
HK (1) HK1203823A1 (https=)
IL (1) IL233351A (https=)
MX (1) MX357071B (https=)
WO (1) WO2013109342A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051394B2 (en) 2011-01-19 2015-06-09 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
HK1203823A1 (en) 2012-01-19 2015-11-06 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv
JP2015524808A (ja) * 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質aivを用いたi型糖尿病の治療法
US10138469B2 (en) * 2014-06-23 2018-11-27 Toagosei Co., Ltd. Synthetic peptide and use thereof
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
CN112891561A (zh) * 2021-03-09 2021-06-04 百码科技(深圳)有限公司 一种基因治疗脂肪肝的生物药剂及其制备方法
CN113018459A (zh) * 2021-03-09 2021-06-25 百码科技(深圳)有限公司 一种基因治疗减肥的生物药剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
US6729075B2 (en) * 2000-10-19 2004-05-04 Wenger Corporation Audience seating system
BR0310100A (pt) 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
EP2051725A4 (en) * 2006-07-11 2011-06-15 Harkness Pharmaceuticals Inc METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
EP2257814B1 (en) 2008-03-21 2012-08-29 Podiceps B.v. Diagnostic of pre-symptomatic metabolic syndrome
CN103833712B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
BR112013004396A2 (pt) * 2010-08-30 2016-05-17 Hoffmann La Roche alimentação alcalina
US9051394B2 (en) 2011-01-19 2015-06-09 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
HK1203823A1 (en) 2012-01-19 2015-11-06 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv
JP2015524808A (ja) 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質aivを用いたi型糖尿病の治療法

Similar Documents

Publication Publication Date Title
JP2015506942A5 (https=)
US20250360078A1 (en) Extended release of neuregulin for treating heart failure
US20180028614A1 (en) Use of interleukin-22 in the treatment of fatty liver disease
Bode Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues—aspart, lispro, and glulisine
JP2010031018A5 (https=)
CN101883609A (zh) 可注射的速效胰岛素组合物
WO2001000223A2 (en) Multiple agent diabetes therapy
JP2016514132A5 (https=)
JP2015520188A5 (https=)
WO2015059302A1 (en) Stable formulation of insulin glulisine
JP2014504601A5 (https=)
JP2020502056A5 (https=)
JP2020502150A5 (https=)
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus
RU2004114865A (ru) Композиция и способ лечения диабета
WO2003061728B1 (en) Oral administration of interferon-tau
CA2543507A1 (en) Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
RU2020140694A (ru) Способ лечения гипергликемии
JP2015524808A5 (https=)
JP2015524432A5 (https=)
DK2694090T3 (en) PHARMACEUTICALS CONTAINING RECOMBINANT MISTELTE LECTINES FOR TREATMENT OF THE ORAL MELANOME
JP5732691B2 (ja) インスリン製剤
EP3402505B1 (en) Pharmaceutical formulations for the treatment of diabetes
Oh et al. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis